Clinical trial
Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and…
NCT00217503 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00217503 |
|---|---|
| Title | Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma |
| Official title | Primary Effusion Lymphoma: A Pilot Trial of Bevacizumab and Modified Dose-Adjusted Infusional CDE Chemotherapy Preceded by a Brief Pre-Phase Assessment of Targeted Oncolytic Virotherapy With Bortezomib, Zidovudine and Valganciclovir |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, filgrastim, pegfilgrastim, bortezomib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ganciclovir, valganciclovir, zidovudine |
| Enrollment | 15 |
| Start date | Jul 1, 2005 |
| Completion | Jun 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Jun 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: